Evidence for antibody as a protective correlate for COVID-19 vaccines

Wouters, 2021, Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, The Lancet, 397, 1023, 10.1016/S0140-6736(21)00306-8 Plotkin, 2010, Correlates of protection induced by vaccination, CVI, 17, 1055, 10.1128/CVI.00131-10 McMahan, 2021, Correlates of protection against SARS-CoV-2 in rhesus macaques, Nature, 590, 630, 10.1038/s41586-020-03041-6 Lumley, 2021, Antibody status and incidence of SARS-CoV-2 infection in health care workers, N Engl J Med, 384, 533, 10.1056/NEJMoa2034545 Gabriel, 2019, Optimizing and evaluating biomarker combinations as trial-level general surrogates, Stat Med, 38, 1135, 10.1002/sim.7996 Novavax. Announcement of UK and South Africa Trial Results. 2021; published online Jan 28. https://ir.novavax.com/events/event-details/novavax-update-conference-call-and-webcast-0 (accessed March 8, 2021). Janssen Biotech, Inc. FDA Briefing Document. Janssen Ad26.COV2.S Covid-19 Vaccine for the Prevention of COVID-19. Sponsor Briefing Document Addendum. 2021; published online Feb 26. https://www.fda.gov/media/146218/download (accessed Feb 26, 2021). Chen, 2020, Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19, Signal Transduction and Targeted Therapy, 5, 1, 10.1038/s41392-020-00301-9 Hansen, 2021, SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals, J Immunol, 206, 109, 10.4049/jimmunol.2000898 Zhou, 2021, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell Walsh, 2020, Safety and immunogenicity of two RNA-based covid-19 vaccine candidates, N Engl J Med, 383, 2439, 10.1056/NEJMoa2027906 Jackson, 2020, An mRNA vaccine against SARS-CoV-2 — preliminary report, N Engl J Med, 383, 1920, 10.1056/NEJMoa2022483 Chen, 2021, The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein, Virology, 559, 1, 10.1016/j.virol.2021.03.009 Madhi, 2021, Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant, N Engl J Med, 10.1056/NEJMoa2102214 Siber, 2007, Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies, Vaccine, 25, 3816, 10.1016/j.vaccine.2007.01.119 Qin, 2007, A framework for assessing immunological correlates of protection in vaccine trials, J Infect Dis, 196, 1304, 10.1086/522428